Research programme: insulin based therapeutics - Albireo Pharma

Drug Profile

Research programme: insulin based therapeutics - Albireo Pharma

Alternative Names: BIOD-104; BIOD-620; BIOD-Glucose-responsive Basal; BIOD-Smart Basal; Glucose-sensing basal insulin; Injectable smart basal insulin; Vialog

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biodel
  • Developer Albireo Pharma
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Insulin receptor agonists; Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Diabetes mellitus

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Diabetes-mellitus in USA (SC, Injection)
  • 18 Nov 2014 Biodel has patent protection for its ultra-rapid-acting insulin formulations in Europe
  • 08 May 2013 Biodel selects BIOD 531 as a lead concentrated ultra-rapid-acting insulin product candidate for Diabetes mellitus
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top